Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer

NCT00298896 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Small Cell
Small Cell Lung Cancer

Interventions

DRUG: SNS-595

Sponsor

Sunesis Pharmaceuticals